Evidence map›Paper›PMID 27081393›Full record

Trial reportAIDS research and therapy2016

Evolution of changes in cognitive function after the initiation of antiretroviral therapy.

Borja Mora-Peris, Elizabeth Stevens, Francesca Ferretti, Jonathan Underwood, Stephen Taylor, Alan Winston

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in AIDS research and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Observational
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Borja Mora-PerisClinical Trials, Faculty of Medicine, Winston Churchill Wing, St. Mary's Hospital, Imperial College, Praed Street, London, W2 1NY UK ; Department of HIV and Genitourinary Medicine, Imperial College Healthcare NHS Trust St Mary's Hospital, London, UK.
Elizabeth StevensBirmingham Heartlands HIV Service, Heart of England NHS Foundation Trust, Birmingham, UK.
Francesca FerrettiDepartment of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy.
Jonathan UnderwoodClinical Trials, Faculty of Medicine, Winston Churchill Wing, St. Mary's Hospital, Imperial College, Praed Street, London, W2 1NY UK.
Stephen TaylorBirmingham Heartlands HIV Service, Heart of England NHS Foundation Trust, Birmingham, UK ; Division of Immunity and Infection, University of Birmingham, Birmingham, UK.
Alan WinstonClinical Trials, Faculty of Medicine, Winston Churchill Wing, St. Mary's Hospital, Imperial College, Praed Street, London, W2 1NY UK ; Department of HIV and Genitourinary Medicine, Imperial College Healthcare NHS Trust St Mary's Hospital, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCognitive function is reported to improve after the initiation of combination antiretroviral therapy (cART). Data on the evolution of such changes are limited. We assessed the dynamics of changes in cognitive parameters, in HIV-positive subjects initiating cART.

methodsCognitive function in seven domains was evaluated for HIV-infected patients without clinically significant cognitive impairment prior to the initiation of cART, and 24 and 48 weeks after. Cognitive scores were transformed using standardised z-scores according to the pooled baseline standard deviation. Global, speed, and accuracy composite z-scores were calculated with changes calculated using a paired t test.

resultsIn 14 subjects, change in global cognitive z-scores from baseline was by 0.08 at week 24 (p = 0.59) and 0.15 at week 48 (p = 0.43). Change in composite speed and accuracy z-scores from baseline at weeks 24/48 were 0.07/0.05 (p = 0.45/0.82) and 0.13/0.23 (p = 0.47/0.45), respectively. In two of the cognitive domains assessing speed (learning and monitoring time), a continued improvement from baseline to weeks 24 and 48 was observed (changes of 0.06-0.08 and 0.10-0.19, respectively), whereas in two domains (detection and identification) an initial improvement at week 24 (changes of -0.10 and 0.04 from baseline, respectively) was followed by a deterioration in score at week 48 (changes of -0.12 and -0.08 from baseline, respectively). None of these changes were statistically significant.

conclusionsA trend for improvement in cognitive function was observed in naïve HIV-positive patients starting cART. The dynamics of this improvement differed both between cognitive domains and the time-points assessed.

Indexed as

AdultAnti-HIV AgentsAtazanavir SulfateCognitionCognition DisordersEmtricitabine, Tenofovir Disoproxil Fumarate Drug CombinationHIV InfectionsHumansMaleMiddle AgedNeuropsychological TestsNevirapineRitonavirYoung AdultAnti-HIV AgentsAtazanavir SulfateEmtricitabine, Tenofovir Disoproxil Fumarate Drug CombinationNevirapineRitonavircARTCognitive functionHIVNaïveNevirapine

Identifiers

PMID27081393
PMCPMC4831200

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.